Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer

American Journal of Gastroenterology

Volumn 106, Issue 10, 2011, Pages 1865-1866

  Tamori, Akihiro ^a   Kawajiri, Hidemi ^a   Takashima, Tsutomu ^a   Motoyama, Hiroyuki ^a   Morikawa, Hiroyasu ^a   Enomoto, Masaru ^a   Hirakawa, Kosei ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN CITRATE; TRASTUZUMAB; VIRUS RNA;

AGED; BREAST CANCER; CANCER STAGING; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER FIBROSIS; LYMPHADENOPATHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; VIRUS REPLICATION;

AGED; ANDROSTADIENES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG COMBINATIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; NEOPLASM STAGING; OXONIC ACID; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TEGAFUR; TUMOR MARKERS, BIOLOGICAL;

EID: 80053897614     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.258     Document Type: Letter

References (9)

1. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterol 2010; 138: 447-62.
2. Suzuki F, Suzuki Y, Akuta N, et al. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol 2010; 47: 76-8.
3. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterol 2005; 129: 1031-41. (Pubitemid 41242693)
4. Rossignol JF, Kabil SM, El-Gohary Y, et al. Clinical trial: randomized, doubleblind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28: 574-80.
5. Himmelsbach K, Sauter D, Baumert TF, et al. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009; 58: 1644-53.
6. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006; 232: 123-38. (Pubitemid 43170962)
7. Mankouri J, Griffin S, Harris M. The hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor. Traffic 2008; 9: 1497-509.
8. Macdonald A, Chan JK, Harris M. Perturbation of epidermal growth factor receptor complex formation and Ras signalling in cells harbouring the hepatitis C virus subgenomic replicon. J Gen Virol 2005; 86: 1027-33. (Pubitemid 40485660)
9. Bahnassi AA, Zekri AR, El-Houssini S, et al. Hepatitis C virus-NS3P in relation to p53, p21waf, mdm2, p21-ras and c-erbB2 in hepatocarcinogenesis. J Gastroenterol Hepatol 2005; 20: 1731-40. (Pubitemid 43961081)